These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 25261300)

  • 1. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.
    Patlewicz G; Simon TW; Rowlands JC; Budinsky RA; Becker RA
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):463-77. PubMed ID: 25707856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays.
    Sachana M; Willett C; Pistollato F; Bal-Price A
    Reprod Toxicol; 2021 Aug; 103():159-170. PubMed ID: 34147625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making.
    Edwards SW; Tan YM; Villeneuve DL; Meek ME; McQueen CA
    J Pharmacol Exp Ther; 2016 Jan; 356(1):170-81. PubMed ID: 26537250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Approaches to Testing and Assessment.
    Worth AP; Patlewicz G
    Adv Exp Med Biol; 2016; 856():317-342. PubMed ID: 27671729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards AOP application--implementation of an integrated approach to testing and assessment (IATA) into a pipeline tool for skin sensitization.
    Patlewicz G; Kuseva C; Kesova A; Popova I; Zhechev T; Pavlov T; Roberts DW; Mekenyan O
    Regul Toxicol Pharmacol; 2014 Aug; 69(3):529-45. PubMed ID: 24928565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing the adverse outcome pathway framework-An international horizon scanning approach.
    LaLone CA; Ankley GT; Belanger SE; Embry MR; Hodges G; Knapen D; Munn S; Perkins EJ; Rudd MA; Villeneuve DL; Whelan M; Willett C; Zhang X; Hecker M
    Environ Toxicol Chem; 2017 Jun; 36(6):1411-1421. PubMed ID: 28543973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
    Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
    Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical hazard prediction and hypothesis testing using quantitative adverse outcome pathways.
    Perkins EJ; Gayen K; Shoemaker JE; Antczak P; Burgoon L; Falciani F; Gutsell S; Hodges G; Kienzler A; Knapen D; McBride M; Willett C; Doyle FJ; Garcia-Reyero N
    ALTEX; 2019; 36(1):91-102. PubMed ID: 30332685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerating Adverse Outcome Pathway Development Using Publicly Available Data Sources.
    Oki NO; Nelms MD; Bell SM; Mortensen HM; Edwards SW
    Curr Environ Health Rep; 2016 Mar; 3(1):53-63. PubMed ID: 26809562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of AOP networks for reproductive and developmental toxicity assay development.
    Knapen D; Vergauwen L; Villeneuve DL; Ankley GT
    Reprod Toxicol; 2015 Aug; 56():52-5. PubMed ID: 25889759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology.
    Groh KJ; Carvalho RN; Chipman JK; Denslow ND; Halder M; Murphy CA; Roelofs D; Rolaki A; Schirmer K; Watanabe KH
    Chemosphere; 2015 Feb; 120():764-77. PubMed ID: 25439131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
    Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
    ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When Are Adverse Outcome Pathways and Associated Assays "Fit for Purpose" for Regulatory Decision-Making and Management of Chemicals?
    Coady K; Browne P; Embry M; Hill T; Leinala E; Steeger T; Maślankiewicz L; Hutchinson T
    Integr Environ Assess Manag; 2019 Jul; 15(4):633-647. PubMed ID: 30908812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Approaches to Testing and Assessment.
    Casati S
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():51-55. PubMed ID: 29604238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating legacy contaminants and emerging chemicals in marine environments using adverse outcome pathways and biological effects-directed analysis.
    Hutchinson TH; Lyons BP; Thain JE; Law RJ
    Mar Pollut Bull; 2013 Sep; 74(2):517-25. PubMed ID: 23820191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.